Dronabinol and Progressive multifocal leukoencephalopathy - a phase IV clinical study of FDA data

Summary:

Progressive multifocal leukoencephalopathy is reported as a side effect among people who take Dronabinol (dronabinol), especially for people who are male, 40-49 old, also take Tysabri, and have Secondary progressive multiple sclerosis.

The phase IV clinical study analyzes which people have Progressive multifocal leukoencephalopathy when taking Dronabinol. It is created by eHealthMe based on reports of 5,427 people who have side effects when taking Dronabinol from the FDA, and is updated regularly.

What is Dronabinol?

Dronabinol has active ingredients of dronabinol. eHealthMe is studying from 5,453 Dronabinol users. Check the latest studies of Dronabinol.

What is Progressive multifocal leukoencephalopathy?

Progressive multifocal leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells) is found to be associated with 595 drugs and 921 conditions by eHealthMe. Check the latest studies of Progressive multifocal leukoencephalopathy.

On Jul, 09, 2026

5,427 people reported to have side effects when taking Dronabinol.
Among them, 13 people (0.24%) have Progressive multifocal leukoencephalopathy.

Could Dronabinol cause Progressive multifocal leukoencephalopathy?

Among these 13 people:

What is the gender of people who have Progressive multifocal leukoencephalopathy when taking Dronabinol? *

female: 0.0 %
male: 100 %

What is the age of people who have Progressive multifocal leukoencephalopathy when taking Dronabinol? *

What are other drugs people take besides Dronabinol? *

Tysabri: 13 people, 100.00%
Baclofen: 12 people, 92.31%
Hyzaar: 1 person, 7.69%

What are other side effects people have besides Progressive multifocal leukoencephalopathy? *

Weakness: 1 person, 7.69%
Pseudoaldosteronism (medical condition that mimics hyperaldosteronism, it produces hypertension associated with low plasma renin activity, and metabolic alkalosis associated with hypokalemia): 1 person, 7.69%
Peripheral Nerve Palsy: 1 person, 7.69%
Pain In Extremity: 1 person, 7.69%
Muscle Aches (muscle pain): 1 person, 7.69%
Immune Reconstitution Syndrome (immune recovery syndrome): 1 person, 7.69%
Hypokalemia (low potassium): 1 person, 7.69%
Gait Disturbance: 1 person, 7.69%
Dysstasia (difficulty in standing): 1 person, 7.69%
Blood Creatine Phosphokinase Increased: 1 person, 7.69%

What are the existing conditions these people have? *

Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 13 people, 100.00%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 12 people, 92.31%
Stress And Anxiety: 1 person, 7.69%
Stable Angina (a constant chest pain): 1 person, 7.69%
High Blood Pressure: 1 person, 7.69%
Back Pain: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Dronabinol and have Progressive multifocal leukoencephalopathy?

- Check whether Progressive multifocal leukoencephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dronabinol:

Dronabinol (5,453 reports)

Progressive multifocal leukoencephalopathy treatments and more:

Progressive multifocal leukoencephalopathy (13,731 reports)

How severe was Progressive multifocal leukoencephalopathy and when was it recovered:

Progressive multifocal leukoencephalopathy in Dronabinol

Expand to all the drugs that have ingredients of dronabinol:

Progressive multifocal leukoencephalopathy and drugs with ingredients of dronabinol (24 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Dronabinol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (595 drugs)

Browse all the conditions that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (921 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dronabinol (the active ingredients of Dronabinol) and Dronabinol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.